The objective of this study was to examine the efficacy of 3,3′-diindolylmethane (DIM) in prevention of prostate cancer tumor development in an animal model. Mouse prostate cancer cells (TRAMP-C2, 2×10−6) were injected subcutaneously into three groups of C57BL/6 mice (10 mice in each group). Two groups were treated earlier with DIM; 2 or 10 mg/kg each, and an additional control group was injected with medium. Animals were treated for five more weeks until sacrificed. Tumor sizes were measured biweekly. At the end of the experiment, mice were sacrificed, and tumors were excised, weighed, measured and tested using immunohistochemical studies. In addition blood samples were collected for biochemical analysis. The results indicated that DIM significantly reduced tumor development in treated animals when compared with controls. Tumors developed in 80% of controls and 40% and 60% of animals treated with 10 or 2 mg/kg of DIM, respectively. Moreover, tumors that developed in treated animals were significantly (P<0.001) smaller than in controls. Additionally, our results indicated that DIM has no effect on animal weight or liver and kidney functions. These results indicated that the DIM agent is not toxic and has an in-vivo preventive effect against the development of prostate cancer in a mouse model.
Pancreatic cancer is a highly lethal disease with limited options for effective therapy and the lowest survival rate of all cancer forms. Therefore, a new, effective strategy for cancer treatment is in need. Previously, we found that a culture liquid extract of Cyathus striatus (CS) has a potent antitumor activity. In the present study, we aimed to investigate the effects of Cyathus striatus extract (CSE) on the growth of pancreatic cancer cells, both in vitro and in vivo. The proliferation assay (XTT), cell cycle analysis, Annexin/PI staining and TUNEL assay confirmed the inhibition of cell growth and induction of apoptosis by CSE. A Western blot analysis demonstrated the involvement of both the extrinsic and intrinsic apoptosis pathways. In addition, a RNAseq analysis revealed the involvement of the MAPK and P53 signaling pathways and pointed toward endoplasmic reticulum stress induced apoptosis. The anticancer activity of the CSE was also demonstrated in mice harboring pancreatic cancer cell line-derived tumor xenografts when CSE was given for 5 weeks by weekly IV injections. Our findings suggest that CSE could potentially be useful as a new strategy for treating pancreatic cancer.
MiRNAs are small non-coding RNA molecules, involved in the regulation of gene expression via binding to messenger RNA (mRNA), thereby preventing protein translation. We found that the promotor region of miR-193a is highly methylated in FaDu head and neck cancer cells, assuming that its expression is suppressed. Moreover, our results indicated that miRNA-193a levels are undetectable in biopsies of head and neck cancer patients. Induction of miR-193a expression by treatment with methyltransferase inhibitor or transduction of head and neck squamous cell carcinoma (HNSCC) cells with miR-193a resulted in a significant decrease in cell viability in a dose and time-dependent manners, as well as induction of apoptosis through the caspase intrinsic pathway. Moreover, miR-193a also inhibited tumour growth in xenograft mice transplanted with FaDu cells. In addition, we found that miR-193a inactivates the AKT/mTOR signaling pathway through the downregulation of PIK3R3, mTOR, S6KB2, and ERBB4. These observations suggest that miR-193a plays an important role in tumor biogenesis and therefore has the potential to serve for diagnostics as well as therapeutics in HNSCC.
About Me
Researcher in the field of molecular biology, genetic engineering and recombinant proteins and cancer research
Researcher in the field of molecular biology, genetic engineering and recombinant proteins and cancer research